FDA OKs Vericiguat for Unique HF Population

(MedPage Today) -- FDA approved vericiguat (Verquvo) on Wednesday to lower cardiovascular events in patients with heart failure with reduced ejection fraction (HFrEF) who had recently been hospitalized or had received IV diuretic therapy, Merck...